$MTEM News

Last published 3mo ago

3mo agoMTEMRapidPulse Secures Oversubscribed $48M Series B Financing to Advance Clinical Development of Next-Generation Stroke Aspiration TechnologyGlobeNewswireMIAMI, July 16, 2026 (GLOBE NEWSWIRE) -- RapidPulse, Inc., a medical technology company developing next-generation aspiration technology for the treatment of acute ischemic stroke, today announced the close of a $48
1y agoCLDI MTEMCalidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational HighlightsGlobeNewswireBolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with
1y agoCLDI MTEMCalidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and DirectorGlobeNewswireSAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced
1y agoMTEMMolecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing RulesGlobeNewswireAUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or the "Company")), a clinical-stage biopharmaceutical company focused on the discovery and
1y agoMTEMMolecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price RequirementsGlobeNewswireAUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or the "Company")), a clinical-stage biopharmaceutical company focused on the discovery and
2y agoMTEMMolecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate UpdateGlobeNewswireMonotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) programEarly indication of monotherapy activity in
2y agoMTEMMolecular Templates, Inc. Provides Interim UpdateGlobeNewswireContinued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in
2y agoMTEMMolecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate UpdateGlobeNewswireAUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
2y agoMTEMMolecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology MechanismGlobeNewswireAUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
2y agoMTEMMolecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business UpdateGlobeNewswireAUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
2y agoMTEMMolecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase AgreementGlobeNewswireAUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
2y agoMTEMMolecular Templates, Inc. Provides Interim UpdateGlobeNewswireAUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
2y agoMTEMMolecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewswireAUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and
2y agoMTEMMolecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business UpdateGlobeNewswireAUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
3y agoMTEMMolecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid TumorsGlobeNewswireAUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with
3y agoMTEMMolecular Templates to Participate in Upcoming Investor ConferencesGlobeNewswireAUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
3y agoMTEMMolecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical OfficerGlobeNewswireAUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with
3y agoMTEMMolecular Templates Announces 1-for-15 Reverse Stock SplitGlobeNewswireAUSTIN, Texas, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (NASDAQ:MTEM) (the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent
3y agoMTEMMolecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business UpdateGlobeNewswireAUSTIN, Texas, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
3y agoMTEMMolecular Templates Announces Executive Leadership ChangesGlobeNewswireDr. Gabriela Gruia to assume the role of interim Chief Medical OfficerJason Kim to assume the role of President and Chief Financial OfficerKristen Quigley to assume the role of Chief Operating OfficerDr. Grace Kim to
3y agoMTEMMolecular Templates Announces Up to $40 Million Private Placement OfferingGlobeNewswireAUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
3y agoMTEMMolecular Templates Announces Debt Payoff and RestructuringGlobeNewswireRestructuring agreement with K2 HealthVentures (K2HV) to fully discharge and satisfy outstanding debt owed to K2HV for the prepayment of $27.5 million and the granting of contingent value rights and warrantsAdditional
3y agoMTEMMolecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary MyelomaGlobeNewswireAUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
3y agoMTEMMolecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireAUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
3y agoMTEMMolecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business UpdateGlobeNewswireAdvancing clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to Bristol Myers Squibb collaboration AUSTIN, Texas, May 15, 2023 (GLOBE NEWSWIRE) -- Molecular Templates,
3y agoMTEMMolecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169GlobeNewswireAUSTIN, Texas, April 07, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), today announced that the U.S. Food and Drug Administration (the "FDA") informed MTEM that
3y agoMTEMMolecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business UpdateGlobeNewswireAUSTIN, Texas, March 30, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
3y agoMTEMMolecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4GlobeNewswireAUSTIN, Texas, March 09, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
3y agoMTEMMolecular Templates Announces Participation in Upcoming ConferencesGlobeNewswireAUSTIN, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
3y agoMTEMMolecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual MeetingGlobeNewswireAUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
3y agoMTEMMolecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI's 5th Annual HealthCONx Conference and Piper Sandler's 34th Annual Healthcare ConferenceGlobeNewswireAUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
4y agoMTEMMolecular Templates, Inc. Reports Third Quarter 2022 Financial ResultsGlobeNewswireAUSTIN, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
4y agoMTEMMolecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer's (SITC) 37th Annual MeetingGlobeNewswireAUSTIN, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and development of
4y agoMTEMMolecular Templates Announces Participation in Four Upcoming ConferencesGlobeNewswireAUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (NASDAQ:MTEM, "Molecular Templates" or "MTEM"))) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeuti
4y agoMTEMMolecular Templates, Inc. Reports Second Quarter 2022 Financial ResultsGlobeNewswireAUSTIN, Texas, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therape
4y agoMTEMMolecular Templates' Presentations at the 2022 ASCO Annual Meeting Demonstrate Advancement in PD-L1 and HER2 ProgramsGlobeNewswireAUSTIN, Texas, June 06, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (NASDAQ:MTEM, "Molecular Templates" or "MTEM"))) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeuti
4y agoMTEMMolecular Templates to Present at Upcoming Investor ConferencesGlobeNewswireAUSTIN, Texas, May 17, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeut
4y agoMTEMMolecular Templates, Inc. Reports First Quarter 2022 Financial ResultsGlobeNewswireAUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeu
4y agoMTEMMolecular Templates' Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2022 Highlight Potential of ETB ApproachGlobeNewswireAUSTIN, Texas, April 12, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (NASDAQ:MTEM, "Molecular Templates" or "MTEM"))) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeut
4y agoMTEMMolecular Templates to Host Webinar on a Unique Approach to Immuno-Oncology for Solid TumorsGlobeNewswireEvent will feature a presentation by David Spigel, MD, chief scientific officer of the Sarah Cannon Research Institute Wednesday, April 13th @ 8:00 am ET AUSTIN, Texas, April 08, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM
4y agoMTEMMolecular Templates, Inc. Reports Fourth Quarter 2021 Financial ResultsGlobeNewswireAUSTIN, Texas, March 28, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therap
4y agoMTEMMolecular Templates Strengthens Board of Directors and Management TeamGlobeNewswireIndustry Veteran Gabriela Gruia, M.D., appointed to Board of Directors Megan Filoon promoted to General Counsel AUSTIN, Texas, March 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or "the Co
4y agoMTEMMolecular Templates to Present at the Upcoming Investor ConferencesGlobeNewswireAUSTIN, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates" or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of the company's proprietary engineered to
4y agoMTEMMolecular Templates Provides Corporate Update and Outlines 2022 MilestonesGlobeNewswireUnique PD-L1-mediated immune changes and early signs of anti-tumor activity with MT-6402 Continued dose-finding with MT-5111 and MT-0169 Pipeline advancing with IND planned for CTLA-4 program in 2H22 MTEM to Present at Evercore ISI 4th Annual He
4y agoMTEMMolecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402GlobeNewswireAUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therape
4y agoMTEMMolecular Templates, Inc. Reports Third Quarter 2021 Financial ResultsGlobeNewswireAUSTIN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therape
5y agoMTEMMolecular Templates to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitGlobeNewswireAUSTIN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates" or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary engineered toxin bodies (ET
5y agoMTEMMolecular Templates, Inc. Reports Second Quarter 2021 Financial ResultsGlobeNewswireAUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therape
5y agoMTEMMolecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid TumorsGlobeNewswireAUSTIN, Texas, July 09, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates" or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeuti
5y agoMTEMMolecular Templates to Present at the Ladenburg Thalmann 2021 Healthcare ConferenceGlobeNewswireAUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates" or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary engineered toxin bodies (ETB